Product Description
Bial was developing bia-5-453, an oral DBH inhibitor, for the treatment of Hypertension and Congestive Heart Failure (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03090568)
Mechanisms of Action: DBH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bial
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hypertension|Heart Failure
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03014375 |
BIA-5453-103 | P1 |
Completed |
Heart Failure|Hypertension |
2008-10-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|